Physician profile
Sandra R Brown
NPI 1194764449
$1,352.94
in general payments reported to CMS, 2019-2025
24 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.66 · 2020: $18.31 · 2021: $120 · 2022: $315 · 2023: $345 · 2024: $310 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $195.35 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $161.49 | 2021-2025 | |
| Abbvie INC. | $121.65 | 2022-2025 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.76 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $98.35 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $80.87 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Supernus Pharmaceuticals, INC. | $79.80 | 2022-2025 | Qelbree, Qelbree |
| Exact Sciences Corporation | $77.88 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $73.92 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.99 | 2022-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $43.96 | 2022 | |
| Medtronic, INC. | $28.86 | 2025 | Concertotm |
| Mayne Pharma Commercial LLC | $26.50 | 2023 | |
| Astellas Pharma US INC | $24.57 | 2023 | Veozah |
| Insulet Corporation | $20.81 | 2024 | Omnipod |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.31 | 2020 | |
| Ethicon US, LLC | $16.95 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.73 | 2023 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $16.60 | 2025 | Rotateq, Capvaxive, Gardasil 9 |
| Sumitomo Pharma America, INC. | $16.51 | 2024 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $16.21 | 2021 | |
| Hologic Sales and Service, LLC | $15.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.30 | 2021 | |
| Urovant Sciences INC | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.